Veradermics Announces Positive Phase 2 Data for VDPHL01

We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for pattern hair loss, or PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation. Patients and healthcare providers routinely identify the following shortcomings with currently available treatment options:nSlow onset of hair growth nInconsistent results nInsufficient density of hair growth for patient satisfaction nTolerability issues related to hormonal, mood and cardiac side effects nInconvenient administration nLimited U.S. Food and Drug Administration, or FDA, approved treatment options, and no FDA-approved oral options for women